(0.05%) 5 471.78 points
(0.08%) 39 145 points
(0.34%) 17 778 points
(-0.10%) $80.75
(-3.66%) $2.66
(-0.75%) $2 313.40
(0.28%) $28.95
(3.59%) $1 021.80
(0.29%) $0.936
(0.70%) $10.68
(0.46%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor...
Stats | |
---|---|
今日成交量 | 30 937 |
平均成交量 | 0 |
市值 | 3.67M |
EPS | $102.89 ( Q3 | 2024-06-14 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0120 (6.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-12-28 | Bondarenko Jamieson | Buy | 28 000 | Common Shares |
2022-12-23 | Williams William V. | Buy | 2 530 | Warrant |
2022-12-20 | Bondarenko Jamieson | Buy | 22 000 | Common Shares |
INSIDER POWER |
---|
100.00 |
Last 3 transactions |
Buy: 52 530 | Sell: 0 |
BriaCell Therapeutics 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-1.310 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-1.310 |
FY | 2022 |
营收: | $0 |
毛利润: | $-15 141.00 (0.00 %) |
EPS: | $-0.750 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。